The University of Chicago Header Logo

Connection

Yusuke Nakamura to Cytochrome P-450 CYP2D6

Back to Details
This is a "connection" page, showing publications Yusuke Nakamura has written about Cytochrome P-450 CYP2D6.
Yusuke Nakamura
Connection Strength
3.155
Cytochrome P-450 CYP2D6
  1. Significant Effect of Polymorphisms in CYP2D6 on Response to Tamoxifen Therapy for Breast Cancer: A Prospective Multicenter Study. Clin Cancer Res. 2017 04 15; 23(8):2019-2026.
    View in: PubMed
    Score: 0.567
  2. Important and critical scientific aspects in pharmacogenomics analysis: lessons from controversial results of tamoxifen and CYP2D6 studies. J Hum Genet. 2013 Jun; 58(6):327-33.
    View in: PubMed
    Score: 0.447
  3. Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial. J Natl Cancer Inst. 2012 Aug 22; 104(16):1264; author reply 1266-8.
    View in: PubMed
    Score: 0.423
  4. Should CYP2D6 inhibitors be administered in conjunction with tamoxifen? Expert Rev Anticancer Ther. 2011 Feb; 11(2):185-93.
    View in: PubMed
    Score: 0.382
  5. Loss of heterozygosity at the CYP2D6 locus in breast cancer: implications for germline pharmacogenetic studies. J Natl Cancer Inst. 2014 Dec 08; 107(2).
    View in: PubMed
    Score: 0.125
  6. Citalopram and escitalopram plasma drug and metabolite concentrations: genome-wide associations. Br J Clin Pharmacol. 2014 Aug; 78(2):373-83.
    View in: PubMed
    Score: 0.122
  7. Establishment of CYP2D6 reference samples by multiple validated genotyping platforms. Pharmacogenomics J. 2014 Dec; 14(6):564-72.
    View in: PubMed
    Score: 0.121
  8. Re: Concordance between CYP2D6 genotypes obtained from tumor-derived and germline DNA. J Natl Cancer Inst. 2014 Apr 03; 106(5).
    View in: PubMed
    Score: 0.119
  9. CYP2D6 genotype and tamoxifen activity: understanding interstudy variability in methodological quality. Clin Pharmacol Ther. 2013 Aug; 94(2):185-7.
    View in: PubMed
    Score: 0.113
  10. Pharmacogenomics of tamoxifen: roles of drug metabolizing enzymes and transporters. Drug Metab Pharmacokinet. 2012; 27(1):122-31.
    View in: PubMed
    Score: 0.101
  11. Dose-adjustment study of tamoxifen based on CYP2D6 genotypes in Japanese breast cancer patients. Breast Cancer Res Treat. 2012 Jan; 131(1):137-45.
    View in: PubMed
    Score: 0.100
  12. Evaluation of CYP2D6 and efficacy of tamoxifen and raloxifene in women treated for breast cancer chemoprevention: results from the NSABP P1 and P2 clinical trials. Clin Cancer Res. 2011 Nov 01; 17(21):6944-51.
    View in: PubMed
    Score: 0.099
  13. Lessons for pharmacogenomics studies: association study between CYP2D6 genotype and tamoxifen response. Pharmacogenet Genomics. 2010 Sep; 20(9):565-8.
    View in: PubMed
    Score: 0.093
  14. Differential quantification of CYP2D6 gene copy number by four different quantitative real-time PCR assays. Pharmacogenet Genomics. 2010 Jul; 20(7):451-4.
    View in: PubMed
    Score: 0.092
  15. Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients. J Clin Oncol. 2010 Mar 10; 28(8):1287-93.
    View in: PubMed
    Score: 0.089
  16. CYP2D6 genotyping for functional-gene dosage analysis by allele copy number detection. Clin Chem. 2009 Aug; 55(8):1546-54.
    View in: PubMed
    Score: 0.085
  17. Impact of CYP2D6*10 on recurrence-free survival in breast cancer patients receiving adjuvant tamoxifen therapy. Cancer Sci. 2008 May; 99(5):995-9.
    View in: PubMed
    Score: 0.078
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.